Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (211-220 of 520) with videos related to

Pageof 52
Sort By:
Circulation|September 15, 2004
Effect of pravastatin on cardiovascular events in people with chronic kidney diseaseMarcello Tonelli, Chris Isles, Gary C Curhan, et al.
European Journal of Heart Failure|January 30, 2009
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)Nathaniel M Hawkins, Zhen Huang, Karen S Pieper, et al.
European Journal of Heart Failure|January 28, 2014
The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patientsGeorge V Moukarbel, Zi-Fan Yu, Kenneth Dickstein, et al.
American Heart Journal|November 19, 2011
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programCono A Ariti, John G F Cleland, Stuart J Pocock, et al.
European Journal of Heart Failure|June 11, 2021
Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trialKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
The American Journal of Cardiology|March 1, 2008
Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study)Nagesh S Anavekar, Hicham Skali, Mikhail Bourgoun, et al.
Journal of the American College of Cardiology|February 22, 2023
Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart FailureSafia Chatur, Brian L Claggett, Finnian R McCausland, et al.
European Heart Journal|November 5, 2015
Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarctionNa Wang, Chung-Lieh Hung, Sung-Hee Shin, et al.
Family Medicine and Community Health|December 25, 2021
Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit-risk ratio, not ageKyungmann Kim, Charles H Hennekens, Lisa Martinez, et al.
Journal of Cardiac Failure|March 25, 2018
Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT TrialAkshay S Desai, Jiankang Liu, Marc A Pfeffer, et al.
Pageof 52

Showing results (211-220 of 520) with videos related to

Sort By:
Pageof 52
Circulation|September 15, 2004
Effect of pravastatin on cardiovascular events in people with chronic kidney diseaseMarcello Tonelli, Chris Isles, Gary C Curhan, et al.
European Journal of Heart Failure|January 30, 2009
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)Nathaniel M Hawkins, Zhen Huang, Karen S Pieper, et al.
European Journal of Heart Failure|January 28, 2014
The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patientsGeorge V Moukarbel, Zi-Fan Yu, Kenneth Dickstein, et al.
American Heart Journal|November 19, 2011
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programCono A Ariti, John G F Cleland, Stuart J Pocock, et al.
European Journal of Heart Failure|June 11, 2021
Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trialKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
The American Journal of Cardiology|March 1, 2008
Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study)Nagesh S Anavekar, Hicham Skali, Mikhail Bourgoun, et al.
Journal of the American College of Cardiology|February 22, 2023
Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart FailureSafia Chatur, Brian L Claggett, Finnian R McCausland, et al.
European Heart Journal|November 5, 2015
Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarctionNa Wang, Chung-Lieh Hung, Sung-Hee Shin, et al.
Family Medicine and Community Health|December 25, 2021
Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit-risk ratio, not ageKyungmann Kim, Charles H Hennekens, Lisa Martinez, et al.
Journal of Cardiac Failure|March 25, 2018
Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT TrialAkshay S Desai, Jiankang Liu, Marc A Pfeffer, et al.
Pageof 52